Santore Matthew T, Roybal Jessica L, Flake Alan W
Department of Surgery, Children's Center for Fetal Research, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Abramson Research Building, Philadelphia, PA 19104-4318, USA.
Clin Perinatol. 2009 Jun;36(2):451-71, xi. doi: 10.1016/j.clp.2009.03.006.
At the present time, the most likely and eminent application of stem cell therapy to the fetus is in utero hematopoietic stem cell transplantation (IUHCT), and this stem cell type will be discussed as a paradigm for all prenatal stem cell therapy. The authors feel that the most likely initial application of IUHCT will use adult HSC derived from bone marrow (BM) or peripheral blood (PB), and will focus this article on this specific approach. The article also reviews the experimental data that support the capacity of IUHCT to induce donor-specific tolerance.
目前，干细胞疗法在胎儿中的最有可能且显著的应用是宫内造血干细胞移植（IUHCT），并且这种干细胞类型将作为所有产前干细胞疗法的范例进行讨论。作者认为，IUHCT最有可能的初始应用将使用源自骨髓（BM）或外周血（PB）的成人造血干细胞（HSC），本文将聚焦于这种特定方法。文章还回顾了支持IUHCT诱导供体特异性耐受能力的实验数据。
